Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Advanced Myeloid Malignancies
NCT03042689Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelofibrosis (MF), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Apr 2017; status: completed.
02
Drugs
regorafenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03042689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042689.